David Kirske Biography and Net Worth

CFO of X4 Pharmaceuticals

David Kirske has served as Chief Financial Officer of X4 since August 2025. Mr. Kirske brings more than two decades of strategic financial and operational experience. He was most recently the Chief Financial Officer of Stratus Therapeutics and previously Executive Vice President and CFO of CTI BioPharma, where he oversaw key corporate functions and played a central role in its $1.7 billion acquisition by Sobi. Earlier, he was a CFO consultant and held senior financial roles at Helix BioMedix, F-5 Networks, Redhook Brewery, and Cray Computer. He holds a B.A. in Business Administration from the University of Puget Sound.

What is David Kirske's net worth?: The estimated net worth of David Kirske is at least $452.35 thousand as of October 1st, 2026. Mr. Kirske owns 155,983 shares of X4 Pharmaceuticals stock worth more than $452,351 as of October 6th. This net worth estimate does not reflect any other investments that Mr. Kirske may own. Learn More about David Kirske's net worth.
How do I contact David Kirske?: The corporate mailing address for Mr. Kirske and other X4 Pharmaceuticals executives is 61 North Beacon Street, 4th Floor, Boston, MA, 02134. X4 Pharmaceuticals can also be reached via phone at (857) 529-8300 and via email at [email protected]. Learn More on David Kirske's contact information.
Has David Kirske been buying or selling shares of X4 Pharmaceuticals?: Over the course of the past ninety days, David Kirske has sold $33,653.62 in shares of X4 Pharmaceuticals stock. Most recently, David Kirske sold 11,767 shares of the business's stock in a transaction on Thursday, October 1st. The shares were sold at an average price of $2.86, for a transaction totalling $33,653.62. Following the completion of the sale, the chief financial officer now directly owns 155,983 shares of the company's stock, valued at $446,111.38. Learn More on David Kirske's trading history.
Who are X4 Pharmaceuticals' active insiders?: X4 Pharmaceuticals' insider roster includes Mark Baldry (Chief Commercial Officer), Adam Craig (Chairman), Mary Dibiase (COO), David Kirske (CFO), Derek Meisner (General Counsel), Adam Mostafa (CFO), Paula Ragan (CEO), and Michael Wyzga (Director). Learn More on X4 Pharmaceuticals' active insiders.
Are insiders buying or selling shares of X4 Pharmaceuticals?: During the last twelve months, X4 Pharmaceuticals insiders bought shares 1 times. They purchased a total of 86,206 shares worth more than $249,997.40. During the last twelve months, insiders at the sold shares 4 times. They sold a total of 92,322 shares worth more than $389,780.08. The most recent insider tranaction occured on October, 1st when CFO David Kirske sold 11,767 shares worth more than $33,653.62. Insiders at X4 Pharmaceuticals own 1.1% of the company. Learn More about insider trades at X4 Pharmaceuticals.
Information on this page was last updated on 10/1/2026.

David Kirske Insider Trading History at X4 Pharmaceuticals

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
10/1/2026	Sell	11,767	$2.86	$33,653.62	155,983
6/30/2026	Sell	8,543	$4.26	$36,393.18	167,750

David Kirske Buying and Selling Activity at X4 Pharmaceuticals

X4 Pharmaceuticals Company Overview

X4 Pharmaceuticals, Inc., a late-stage clinical biopharmaceutical company, focuses on the research, development, and commercialization of novel therapeutics for the treatment of rare diseases. Its lead product candidate is mavorixafor, a small molecule inhibitor of the chemokine receptor C-X-C chemokine receptor type 4 (CXCR4), which is in Phase III clinical trial for the treatment of patients with warts, hypogammaglobulinemia, infections, and myelokathexis syndrome; and Phase II clinical trial to treat congenital, idiopathic, or cyclic neutropenia. The company is also developing X4P-003, a CXCR4 antagonist for the treatment of CXCR4 dependent disorders and primary immunodeficiencies; and X4P-002, a CXCR4 antagonist for the treatment of blood-brain barrier diseases. It has a license agreement with Abbisko Therapeutics Co Ltd. to develop, manufacture, and commercialize mavorixafor in combination with checkpoint inhibitors or other agents in oncology indications. The company is headquartered in Boston, Massachusetts.

Today's Range

Now: $2.81

$2.76

$2.90

50 Day Range

MA: $3.79

$2.83

$4.64

2 Week Range

Now: $2.81

$2.73

$4.83

Volume

66,768 shs

Average Volume

637,244 shs

Market Capitalization

$278.11 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.46